266 related articles for article (PubMed ID: 28119364)
1. Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study.
Lamberts LE; Koch M; de Jong JS; Adams ALL; Glatz J; Kranendonk MEG; Terwisscha van Scheltinga AGT; Jansen L; de Vries J; Lub-de Hooge MN; Schröder CP; Jorritsma-Smit A; Linssen MD; de Boer E; van der Vegt B; Nagengast WB; Elias SG; Oliveira S; Witkamp AJ; Mali WPTM; Van der Wall E; van Diest PJ; de Vries EGE; Ntziachristos V; van Dam GM
Clin Cancer Res; 2017 Jun; 23(11):2730-2741. PubMed ID: 28119364
[No Abstract] [Full Text] [Related]
2. Feasibility of bevacizumab-IRDye800CW as a tracer for fluorescence-guided meningioma surgery.
Dijkstra BM; Nonnekens J; Nagengast W; Kruijff S; Meersma GJ; den Dunnen WFA; Kruyt FAE; Groen RJM
J Neurosurg; 2023 May; 138(5):1263-1272. PubMed ID: 36308486
[TBL] [Abstract][Full Text] [Related]
3. 89Zr-bevacizumab PET imaging in primary breast cancer.
Gaykema SB; Brouwers AH; Lub-de Hooge MN; Pleijhuis RG; Timmer-Bosscha H; Pot L; van Dam GM; van der Meulen SB; de Jong JR; Bart J; de Vries J; Jansen L; de Vries EG; Schröder CP
J Nucl Med; 2013 Jul; 54(7):1014-8. PubMed ID: 23651946
[TBL] [Abstract][Full Text] [Related]
4. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.
Hekman MCH; Boerman OC; Bos DL; Massuger LFAG; Weil S; Grasso L; Rybinski KA; Oosterwijk E; Mulders PFA; Rijpkema M
Mol Pharm; 2017 Oct; 14(10):3457-3463. PubMed ID: 28826214
[TBL] [Abstract][Full Text] [Related]
5. Intraoperative Molecular Fluorescence Imaging of Pancreatic Cancer by Targeting Vascular Endothelial Growth Factor: A Multicenter Feasibility Dose-Escalation Study.
Mulder BGS; Koller M; Duiker EW; Sarasqueta AF; Burggraaf J; Meijer VE; Vahrmeijer AL; Hoogwater FJH; Bonsing BA; van Dam GM; Mieog JSD; Pranger BK
J Nucl Med; 2023 Jan; 64(1):82-89. PubMed ID: 35680414
[TBL] [Abstract][Full Text] [Related]
6. First-in-human study of PET and optical dual-modality image-guided surgery in glioblastoma using
Li D; Zhang J; Chi C; Xiao X; Wang J; Lang L; Ali I; Niu G; Zhang L; Tian J; Ji N; Zhu Z; Chen X
Theranostics; 2018; 8(9):2508-2520. PubMed ID: 29721096
[No Abstract] [Full Text] [Related]
7. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.
Terwisscha van Scheltinga AG; van Dam GM; Nagengast WB; Ntziachristos V; Hollema H; Herek JL; Schröder CP; Kosterink JG; Lub-de Hoog MN; de Vries EG
J Nucl Med; 2011 Nov; 52(11):1778-85. PubMed ID: 21990576
[TBL] [Abstract][Full Text] [Related]
8. Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
Muselaers CH; Stillebroer AB; Rijpkema M; Franssen GM; Oosterwijk E; Mulders PF; Oyen WJ; Boerman OC
J Nucl Med; 2014 Jun; 55(6):1035-40. PubMed ID: 24752673
[TBL] [Abstract][Full Text] [Related]
9. Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer.
Korb ML; Hartman YE; Kovar J; Zinn KR; Bland KI; Rosenthal EL
J Surg Res; 2014 May; 188(1):119-28. PubMed ID: 24360117
[TBL] [Abstract][Full Text] [Related]
10. Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer.
Nishio N; van den Berg NS; van Keulen S; Martin BA; Fakurnejad S; Zhou Q; Lu G; Chirita SU; Kaplan MJ; Divi V; Colevas AD; Rosenthal EL
Mol Imaging Biol; 2020 Feb; 22(1):156-164. PubMed ID: 31054001
[TBL] [Abstract][Full Text] [Related]
11. Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study.
Lu G; van den Berg NS; Martin BA; Nishio N; Hart ZP; van Keulen S; Fakurnejad S; Chirita SU; Raymundo RC; Yi G; Zhou Q; Fisher GA; Rosenthal EL; Poultsides GA
Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):753-764. PubMed ID: 32416764
[TBL] [Abstract][Full Text] [Related]
12. Effect of Dye and Conjugation Chemistry on the Biodistribution Profile of Near-Infrared-Labeled Nanobodies as Tracers for Image-Guided Surgery.
Debie P; Van Quathem J; Hansen I; Bala G; Massa S; Devoogdt N; Xavier C; Hernot S
Mol Pharm; 2017 Apr; 14(4):1145-1153. PubMed ID: 28245129
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.
Paudyal B; Paudyal P; Oriuchi N; Hanaoka H; Tominaga H; Endo K
Cancer Sci; 2011 Jan; 102(1):117-21. PubMed ID: 21070475
[TBL] [Abstract][Full Text] [Related]
14. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.
Nagengast WB; de Vries EG; Hospers GA; Mulder NH; de Jong JR; Hollema H; Brouwers AH; van Dongen GA; Perk LR; Lub-de Hooge MN
J Nucl Med; 2007 Aug; 48(8):1313-9. PubMed ID: 17631557
[TBL] [Abstract][Full Text] [Related]
15. Back-Table Fluorescence-Guided Imaging for Circumferential Resection Margin Evaluation Using Bevacizumab-800CW in Patients with Locally Advanced Rectal Cancer.
de Jongh SJ; Tjalma JJJ; Koller M; Linssen MD; Vonk J; Dobosz M; Jorritsma-Smit A; Kleibeuker JH; Hospers GAP; Havenga K; Hemmer PHJ; Karrenbeld A; van Dam GM; van Etten B; Nagengast WB
J Nucl Med; 2020 May; 61(5):655-661. PubMed ID: 31628218
[TBL] [Abstract][Full Text] [Related]
16. Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers.
Koller M; Qiu SQ; Linssen MD; Jansen L; Kelder W; de Vries J; Kruithof I; Zhang GJ; Robinson DJ; Nagengast WB; Jorritsma-Smit A; van der Vegt B; van Dam GM
Nat Commun; 2018 Sep; 9(1):3739. PubMed ID: 30228269
[TBL] [Abstract][Full Text] [Related]
17. Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers.
Gao RW; Teraphongphom N; de Boer E; van den Berg NS; Divi V; Kaplan MJ; Oberhelman NJ; Hong SS; Capes E; Colevas AD; Warram JM; Rosenthal EL
Theranostics; 2018; 8(9):2488-2495. PubMed ID: 29721094
[No Abstract] [Full Text] [Related]
18. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Cameron D; Brown J; Dent R; Jackisch C; Mackey J; Pivot X; Steger GG; Suter TM; Toi M; Parmar M; Laeufle R; Im YH; Romieu G; Harvey V; Lipatov O; Pienkowski T; Cottu P; Chan A; Im SA; Hall PS; Bubuteishvili-Pacaud L; Henschel V; Deurloo RJ; Pallaud C; Bell R
Lancet Oncol; 2013 Sep; 14(10):933-42. PubMed ID: 23932548
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab and near infrared probe conjugated iron oxide nanoparticles for vascular endothelial growth factor targeted MR and optical imaging.
Lin R; Huang J; Wang L; Li Y; Lipowska M; Wu H; Yang J; Mao H
Biomater Sci; 2018 May; 6(6):1517-1525. PubMed ID: 29652061
[TBL] [Abstract][Full Text] [Related]
20. Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer.
Koch M; de Jong JS; Glatz J; Symvoulidis P; Lamberts LE; Adams AL; Kranendonk ME; Terwisscha van Scheltinga AG; Aichler M; Jansen L; de Vries J; Lub-de Hooge MN; Schröder CP; Jorritsma-Smit A; Linssen MD; de Boer E; van der Vegt B; Nagengast WB; Elias SG; Oliveira S; Witkamp AJ; Mali WP; Van der Wall E; Garcia-Allende PB; van Diest PJ; de Vries EG; Walch A; van Dam GM; Ntziachristos V
Cancer Res; 2017 Feb; 77(3):623-631. PubMed ID: 27879266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
